top of page

European Lung Cancer Congress 2024

The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology, including thoracic surgeons, respiratory physicians and pneumologists, medical and radiation oncologists, interventional radiologists and pathologists, to discuss the latest insights into the recent developments in the prevention, diagnosis and treatment of lung cancer.

The event will take place in Prague, Czech Republic, and through a dedicated virtual platform between 20-23 March.

Programme highlights Novel results in the treatment of EGFR-mutant non-small cell lung cancer Related content: 3MO, 5MO, 8P, 4O Insights into the opportunities related to the use of immunotherapy, and the challenges related to IO resistance mechanisms that may occur in the treatment of patients with lung cancer Related content: Sessions on 20 March, 14:30-16:00 CET and 16:30-18:00 CET, session on 21 March, 11:15-12:45 CET

Prevention, screening and early diagnosis of thoracic tumours: from new technologies aimed at improving screening to prevention measures beyond smoking Related content: Session on 23 March, 10:00-11:30 CET Emerging evidence on the efficacy and the management of toxicities of antibody-drug conjugates Related content: 59P, 11P, Session on 23 March, 10:00-11:30 CET

Keynote lecture “Advancing precision oncology in lung cancer: A multidisciplinary-driven approach” by Enriqueta Felip, recipient of the Heine H. Hansen Award, 20 March 2024, 13:30-14:15 CET “The rise of proteomics in never-smokers in lung cancer” by Yu-Ju Chen, 22 March 2024, 09:30-10:00 CET “Incorporating ctDNA and other plasma-based assays into clinical trial design” by Maximilian Diehn, 22 March 2024, 14:30-15:00 CET

The results of more than 240 studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.

Aktuelle Beiträge

Alle ansehen

Precision Biologics to Present at AACR

Precision Biologics, Inc. reports its lead monoclonal antibody, NEO-201, targets circulating human naïve regulatory T cells (Tregs) in both healthy donors and cancer patients. A poster presentation di


bottom of page